ArticleOncology letters2026
Small intestinal SMARCA4-deficient undifferentiated carcinoma with intussusception: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Intestinal SMARCA4-deficient undifferentiated carcinoma: a case series and systematic review of the literature.World journal of surgical oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Switch/sucrose non-fermentable (SWI/SNF) related matrix associated actin-dependent regulator of chromatin sub-family A member 4-deficient undifferentiated carcinoma (SMARCA4-DUC) of the small intestine is a rare and highly aggressive subtype of gastrointestinal malignancy. The present study reported the case of SMARCA4-DUC in a patient who presented with intestinal intussusception and multi-organ metastasis to the lungs, liver, spleen and skin, which led to rapid progression and death in 43 days. The present case highlighted the unique histological and molecular features of SMARCA4-DUC, characterized by the absence of SMARCA4 expression and undifferentiated cellular morphology. The present case report aimed to describe the clinical presentation, imaging findings, pathological features and treatment course, to further the current understanding of SMARCA4-associated malignancies and improve the recognition of SMARCA4-DUC among clinicians and pathologists. Next-generation sequencing of the primary small intestinal tumor identified pathogenic mutations in PTEN, TP53, ataxia telangiectasia mutated, ephrin type-A receptor 5 and EGFR p.F997L, suggesting a DNA-repair-deficient genomic background and providing potential targets for future precision therapy. Further research is warranted to determine the molecular mechanisms underlying SMARCA4-DUC, for the development of targeted therapeutic strategies and to improve the understanding of the aggressiveness of SMARCA4-DUC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.